Access Bio KRX:950130KOSDAQ
엑세스바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Access Bio reported revenue of ₩6m, up 567.5% year on year, and an operating loss of ₩16m. Access Bio (엑세스바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
Access Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6m | +567.5% | −₩16m margin −247.9% | −₩26m |
| Q1 2026 | ₩4m | -75.4% | −₩8m margin −209.6% | −₩5m |
| Q4 2025 derived | ₩4m | -83.4% | −₩15m | −₩38m |
| Q3 2025 | ₩3m | -84.3% | −₩10m | −₩8m |
| Q2 2025 | ₩1m | -94.8% | −₩14m | −₩8m |
| Q1 2025 | ₩15m | -43.5% | −₩6m margin −38.0% | −₩5m |
| Q4 2024 derived | ₩21m | -20.3% | ₩3m margin 15.3% | ₩0m |
| Q3 2024 | ₩16m | +583.6% | −₩6m margin −37.9% | −₩4m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Access Bio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Access Bio news Korean headlines
No articles yet.